Loading
An immune-brake blocker that looked excellent in a phase 2 lung cancer trial and then failed every phase 3.
CITYSCAPE (phase 2, 2020) showed tiragolumab plus atezolizumab roughly doubled response rate in PD-L1-high NSCLC. Phase 3 SKYSCRAPER-01 (PD-L1-high NSCLC) missed PFS and OS; SKYSCRAPER-02 (extensive-stage SCLC) was negative; SKYSCRAPER-06 (non-squamous NSCLC) was worse than control. Roche discontinued most of the programme in 2024 and 2025. Other anti-TIGIT antibodies (domvanalimab, ociperlimab) showed no clearer benefit.
Lesson: a small randomised phase 2 with a surrogate endpoint in a selected population can mislead; redundancy between checkpoints means blocking a second one does not necessarily add to PD-1/PD-L1 blockade.
Backbone ribbon from PDB 8JEO. RCSB PDB 8JEO. The ribbon widens where the chain is folded into a regular pattern and narrows where it is a loose loop.
IgG1 anti-TIGIT with intact Fc; blocks TIGIT-PVR interaction on T and NK cells. Connects to TIGIT and PD-L1.
1.Tiragolumab binds TIGIT.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Tiragolumab" OR ABSTRACT:"Tiragolumab" OR TITLE:"RG6058" OR ABSTRACT:"RG6058" OR TITLE:"MTIG7192A" OR ABSTRACT:"MTIG7192A") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Tiragolumab, not a curated reading list.
Shares No accelerated approval for a combination without proof each part contributes, Atezolizumab, Roche / Genentech, Immune checkpoint inhibitors and the tag failure.
Shares No accelerated approval for a combination without proof each part contributes, Cold tumours and the immunosuppressive microenvironment, Failures are hidden, Immune checkpoint inhibitors and the tag failure.
Shares Automatic offer of shelved cancer assets to non-profits after two years, Cold tumours and the immunosuppressive microenvironment, Failures are hidden and the tag failure.
Shares Atezolizumab, Roche / Genentech, Immune checkpoint inhibitors and the tag failure.
Shares T-cell exhaustion, Failures are hidden and the tag failure.
Shares Failures are hidden, Small-cell lung cancer and the tag failure.
Shares Failures are hidden, Non-small-cell lung cancer and the tag failure.
Shares Failures are hidden, Non-small-cell lung cancer and the tag failure.